Robert Vries
Chief Executive Officer HUB Organoids (A Merck Company)
Seminars
Thursday 4th December 2025
Translating Tumor Complexity: How Organoids Are Shaping the Future of Clinical Oncology
12:00 pm
- Clinically Predictive Models: HUB Organoids’ patient-derived models closely mimic human tumor biology, enabling more accurate drug response predictions and reducing clinical trial attrition
- Accelerating Drug Discovery: Our organoid platform supports high-throughput screening and rapid data delivery, streamlining preclinical pipelines and shortening time-to-clinic for new therapies
- Enabling Personalized Medicine: By capturing patient-specific heterogeneity, HUB Organoids empower precision oncology—supporting biomarker discovery, therapy selection, and patient stratification for clinical trials
